Impressive response of CD30‐negative, treatment‐refractory mycosis fungoides to brentuximab vedotin
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Therapy"
DOI: 10.1111/dth.12835
Abstract: Brentuximab vedotin is a CD30‐antibody/drug conjugate which has demonstrated excellent response in treating CD30‐positive mycosis fungoides (MF) and anaplastic large cell lymphoma (ALCL). In this report, we present a patient with CD30‐negative MF refractory to… read more here.
Keywords: cd30; response; mycosis fungoides; cd30 negative ... See more keywords